The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
IMFINZI AstraZeneca Pty Ltd
Product name
IMFINZI
Sponsor
Accepted date
Jan-2024
Active ingredients
durvalumab
Proposed indication
Is indicated for the first-line treatment of adult patients with advanced or recurrent endometrial cancer.
Application type
C (new indication)
Publication date
Jan-2024